Safety and effectiveness of tinzaparin sodium in the management of recurrent pregnancy loss
To assess the safety and efficacy of tinzaparin sodium for the management of recurrent pregnancy loss. The study included 62 women with a history of recurrent pregnancy loss and at least one factor of thrombophilic disorder. Of these, 31 received 50 IU/kg of tinzaparin sodium daily (Group A), and 33...
Gespeichert in:
| Veröffentlicht in: | Clinical and experimental obstetrics & gynecology 2007, Vol.34 (3), p.143-145 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 145 |
|---|---|
| container_issue | 3 |
| container_start_page | 143 |
| container_title | Clinical and experimental obstetrics & gynecology |
| container_volume | 34 |
| creator | Dendrinos, S Kalogirou, I Makrakis, E Theodoridis, T Mahmound, E A Christopoulou-Cokkinou, V Creatsas, G |
| description | To assess the safety and efficacy of tinzaparin sodium for the management of recurrent pregnancy loss.
The study included 62 women with a history of recurrent pregnancy loss and at least one factor of thrombophilic disorder. Of these, 31 received 50 IU/kg of tinzaparin sodium daily (Group A), and 33 received 100 mg of aspirin daily (Group B).
Group A subjects (receiving tinzaparin sodium) had six new abortions, whereas Group B subjects (receiving aspirin) had 11 (significant difference). Cases of intrauterine growth restriction (none in Group A and 2 in Group B), placental abruption (one in Group A and 4 in Group B), and preeclampsia (one in Group A and 3 in Group B) were comparable between the two groups. Finally coagulation disorders (none in Group A and 6 in Group B) were significantly fewer in Group A.
A 50 IU/kg daily dose of tinzaparin sodium seems to be effective for the management of recurrent abortion and has high standards of safety. |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_68393216</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>68393216</sourcerecordid><originalsourceid>FETCH-LOGICAL-p209t-f53a3eb13641b79d55a2e029488100077fab5fc825748feaad846a89fe5c0dff3</originalsourceid><addsrcrecordid>eNo1kL1OwzAYRT2AaCm8AvLEFsmO_0dU8SdVYgAmhuhL8rkEJU6wHaTy9LRqme650tEd7hlZMuFYobUWC3KZ0hdjUhrNL8iCGycMs3pJPl7BY95RCC1F77HJ3Q8GTImOnuYu_MIEsQs0jW03D3RP-RPpAAG2OGDIBy1iM8d4KFPEbYDQ7Gg_pnRFzj30Ca9PuSLvD_dv66di8_L4vL7bFFPJXC68EiCw5kJLXhvXKgUlstJJazljzBgPtfKNLZWR1iNAa6UG6zyqhrXeixW5Pe5OcfyeMeVq6FKDfQ8BxzlV2gonSq734s1JnOsB22qK3QBxV_3fIf4A6Dtcgg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68393216</pqid></control><display><type>article</type><title>Safety and effectiveness of tinzaparin sodium in the management of recurrent pregnancy loss</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Dendrinos, S ; Kalogirou, I ; Makrakis, E ; Theodoridis, T ; Mahmound, E A ; Christopoulou-Cokkinou, V ; Creatsas, G</creator><creatorcontrib>Dendrinos, S ; Kalogirou, I ; Makrakis, E ; Theodoridis, T ; Mahmound, E A ; Christopoulou-Cokkinou, V ; Creatsas, G</creatorcontrib><description>To assess the safety and efficacy of tinzaparin sodium for the management of recurrent pregnancy loss.
The study included 62 women with a history of recurrent pregnancy loss and at least one factor of thrombophilic disorder. Of these, 31 received 50 IU/kg of tinzaparin sodium daily (Group A), and 33 received 100 mg of aspirin daily (Group B).
Group A subjects (receiving tinzaparin sodium) had six new abortions, whereas Group B subjects (receiving aspirin) had 11 (significant difference). Cases of intrauterine growth restriction (none in Group A and 2 in Group B), placental abruption (one in Group A and 4 in Group B), and preeclampsia (one in Group A and 3 in Group B) were comparable between the two groups. Finally coagulation disorders (none in Group A and 6 in Group B) were significantly fewer in Group A.
A 50 IU/kg daily dose of tinzaparin sodium seems to be effective for the management of recurrent abortion and has high standards of safety.</description><identifier>ISSN: 0390-6663</identifier><identifier>PMID: 17937086</identifier><language>eng</language><publisher>Canada</publisher><subject>Abortion, Habitual - drug therapy ; Adult ; Aspirin - therapeutic use ; Female ; Fibrinolytic Agents - therapeutic use ; Heparin, Low-Molecular-Weight - therapeutic use ; Humans ; Pregnancy ; Pregnancy Outcome ; Thrombophilia - drug therapy</subject><ispartof>Clinical and experimental obstetrics & gynecology, 2007, Vol.34 (3), p.143-145</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,782,786,4026</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17937086$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dendrinos, S</creatorcontrib><creatorcontrib>Kalogirou, I</creatorcontrib><creatorcontrib>Makrakis, E</creatorcontrib><creatorcontrib>Theodoridis, T</creatorcontrib><creatorcontrib>Mahmound, E A</creatorcontrib><creatorcontrib>Christopoulou-Cokkinou, V</creatorcontrib><creatorcontrib>Creatsas, G</creatorcontrib><title>Safety and effectiveness of tinzaparin sodium in the management of recurrent pregnancy loss</title><title>Clinical and experimental obstetrics & gynecology</title><addtitle>Clin Exp Obstet Gynecol</addtitle><description>To assess the safety and efficacy of tinzaparin sodium for the management of recurrent pregnancy loss.
The study included 62 women with a history of recurrent pregnancy loss and at least one factor of thrombophilic disorder. Of these, 31 received 50 IU/kg of tinzaparin sodium daily (Group A), and 33 received 100 mg of aspirin daily (Group B).
Group A subjects (receiving tinzaparin sodium) had six new abortions, whereas Group B subjects (receiving aspirin) had 11 (significant difference). Cases of intrauterine growth restriction (none in Group A and 2 in Group B), placental abruption (one in Group A and 4 in Group B), and preeclampsia (one in Group A and 3 in Group B) were comparable between the two groups. Finally coagulation disorders (none in Group A and 6 in Group B) were significantly fewer in Group A.
A 50 IU/kg daily dose of tinzaparin sodium seems to be effective for the management of recurrent abortion and has high standards of safety.</description><subject>Abortion, Habitual - drug therapy</subject><subject>Adult</subject><subject>Aspirin - therapeutic use</subject><subject>Female</subject><subject>Fibrinolytic Agents - therapeutic use</subject><subject>Heparin, Low-Molecular-Weight - therapeutic use</subject><subject>Humans</subject><subject>Pregnancy</subject><subject>Pregnancy Outcome</subject><subject>Thrombophilia - drug therapy</subject><issn>0390-6663</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1kL1OwzAYRT2AaCm8AvLEFsmO_0dU8SdVYgAmhuhL8rkEJU6wHaTy9LRqme650tEd7hlZMuFYobUWC3KZ0hdjUhrNL8iCGycMs3pJPl7BY95RCC1F77HJ3Q8GTImOnuYu_MIEsQs0jW03D3RP-RPpAAG2OGDIBy1iM8d4KFPEbYDQ7Gg_pnRFzj30Ca9PuSLvD_dv66di8_L4vL7bFFPJXC68EiCw5kJLXhvXKgUlstJJazljzBgPtfKNLZWR1iNAa6UG6zyqhrXeixW5Pe5OcfyeMeVq6FKDfQ8BxzlV2gonSq734s1JnOsB22qK3QBxV_3fIf4A6Dtcgg</recordid><startdate>2007</startdate><enddate>2007</enddate><creator>Dendrinos, S</creator><creator>Kalogirou, I</creator><creator>Makrakis, E</creator><creator>Theodoridis, T</creator><creator>Mahmound, E A</creator><creator>Christopoulou-Cokkinou, V</creator><creator>Creatsas, G</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>2007</creationdate><title>Safety and effectiveness of tinzaparin sodium in the management of recurrent pregnancy loss</title><author>Dendrinos, S ; Kalogirou, I ; Makrakis, E ; Theodoridis, T ; Mahmound, E A ; Christopoulou-Cokkinou, V ; Creatsas, G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p209t-f53a3eb13641b79d55a2e029488100077fab5fc825748feaad846a89fe5c0dff3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Abortion, Habitual - drug therapy</topic><topic>Adult</topic><topic>Aspirin - therapeutic use</topic><topic>Female</topic><topic>Fibrinolytic Agents - therapeutic use</topic><topic>Heparin, Low-Molecular-Weight - therapeutic use</topic><topic>Humans</topic><topic>Pregnancy</topic><topic>Pregnancy Outcome</topic><topic>Thrombophilia - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dendrinos, S</creatorcontrib><creatorcontrib>Kalogirou, I</creatorcontrib><creatorcontrib>Makrakis, E</creatorcontrib><creatorcontrib>Theodoridis, T</creatorcontrib><creatorcontrib>Mahmound, E A</creatorcontrib><creatorcontrib>Christopoulou-Cokkinou, V</creatorcontrib><creatorcontrib>Creatsas, G</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical and experimental obstetrics & gynecology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dendrinos, S</au><au>Kalogirou, I</au><au>Makrakis, E</au><au>Theodoridis, T</au><au>Mahmound, E A</au><au>Christopoulou-Cokkinou, V</au><au>Creatsas, G</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Safety and effectiveness of tinzaparin sodium in the management of recurrent pregnancy loss</atitle><jtitle>Clinical and experimental obstetrics & gynecology</jtitle><addtitle>Clin Exp Obstet Gynecol</addtitle><date>2007</date><risdate>2007</risdate><volume>34</volume><issue>3</issue><spage>143</spage><epage>145</epage><pages>143-145</pages><issn>0390-6663</issn><abstract>To assess the safety and efficacy of tinzaparin sodium for the management of recurrent pregnancy loss.
The study included 62 women with a history of recurrent pregnancy loss and at least one factor of thrombophilic disorder. Of these, 31 received 50 IU/kg of tinzaparin sodium daily (Group A), and 33 received 100 mg of aspirin daily (Group B).
Group A subjects (receiving tinzaparin sodium) had six new abortions, whereas Group B subjects (receiving aspirin) had 11 (significant difference). Cases of intrauterine growth restriction (none in Group A and 2 in Group B), placental abruption (one in Group A and 4 in Group B), and preeclampsia (one in Group A and 3 in Group B) were comparable between the two groups. Finally coagulation disorders (none in Group A and 6 in Group B) were significantly fewer in Group A.
A 50 IU/kg daily dose of tinzaparin sodium seems to be effective for the management of recurrent abortion and has high standards of safety.</abstract><cop>Canada</cop><pmid>17937086</pmid><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0390-6663 |
| ispartof | Clinical and experimental obstetrics & gynecology, 2007, Vol.34 (3), p.143-145 |
| issn | 0390-6663 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68393216 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Abortion, Habitual - drug therapy Adult Aspirin - therapeutic use Female Fibrinolytic Agents - therapeutic use Heparin, Low-Molecular-Weight - therapeutic use Humans Pregnancy Pregnancy Outcome Thrombophilia - drug therapy |
| title | Safety and effectiveness of tinzaparin sodium in the management of recurrent pregnancy loss |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-05T03%3A24%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Safety%20and%20effectiveness%20of%20tinzaparin%20sodium%20in%20the%20management%20of%20recurrent%20pregnancy%20loss&rft.jtitle=Clinical%20and%20experimental%20obstetrics%20&%20gynecology&rft.au=Dendrinos,%20S&rft.date=2007&rft.volume=34&rft.issue=3&rft.spage=143&rft.epage=145&rft.pages=143-145&rft.issn=0390-6663&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E68393216%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=68393216&rft_id=info:pmid/17937086&rfr_iscdi=true |